Novartis is trading 4.27% up now at $158.55 after announcing positive Phase III REMODEL-1/-2 results for remibrutinib in relapsing multiple sclerosis.

  • Remibrutinib significantly reduced relapse rates and MRI lesions versus teriflunomide, showed a favorable safety profile, and is planned for global regulatory submissions.
  • Novartis paused eight autoimmune cell-therapy trials after three patient deaths, creating a material offsetting safety concern.